This is a summary of the European public assessment report (EPAR) for Eviplera. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Eviplera.
Therapeutic Indication
### Therapeutic indication Eviplera is indicated for the treatment of adults infected with human immunodeficiency virus type 1 (HIV-1) without known mutations associated with resistance to the non-nucleoside reverse transcriptase inhibitor (NNRTI) class, tenofovir or emtricitabine, and with a viral load ? 100,000 HIV-1 RNA copies/mL. As with other antiretroviral medicinal products, genotypic resistance testing and/or historical resistance data should guide the use of Eviplera.
Therapeutic Area (MeSH)
N/AATC Code
J05AR08
ATC Item
emtricitabine, tenofovir disoproxil and rilpivirine
Pharmacotherapeutic Group
Antivirals for systemic use
Active Substance (Summary)
N/AINN / Common Names
N/AEMA Name
Eviplera
Medicine Name
Eviplera
Aliases
N/ANo risk management plan link.
